CNSDose Now Available
Through Australian Clinical Labs

Australian Clinical Labs Launches CNSDose^® Nationwide in Partnership with Incite Genomics

CNSDose Clinician Page CNSDose Patient Page

Australian Clinical Labs (ACL) today announced the national launch of CNSDose, an innovative mental health pharmacogenomic test developed by Incite Genomics, now available to clinicians across its network.

CNSDose is a clinically validated pharmacogenomic test designed to support healthcare professionals in optimising medication selection and dosing for patients with mental health conditions. By analysing key genetic variants involved in both hepatic drug metabolism and the transport of medications across the blood–brain barrier, CNSDose delivers actionable insights to enhance treatment efficacy, minimise adverse drug reactions, and enable more precise, personalised patient care.

CNSDose is now available to order through Australian Clinical Labs, expanding access for clinicians, hospitals and patients nationwide.

ACL will market and distribute CNSDose across its extensive national network of clinicians, hospitals, and collection centres, significantly increasing access to this innovative test throughout Australia.

“We are delighted to partner with Australian Clinical Labs, one of the country’s leading pathology providers,” said Richard Hannebery, CEO at Incite Genomics. “This milestone represents a major step forward in making precision medicine more accessible to Australian patients suffering mental illness. ACL’s scale and reputation for clinical excellence make them an ideal partner to bring CNSDose to the Australian market.”

Associate Professor Mirette Saad, Pathologist and National Director of Molecular Genetics at Australian Clinical Labs, added: “Pharmacogenomics is an important and rapidly growing area of personalised medicine. CNSDose offers clinicians a practical and evidence-based tool to guide prescribing decisions in mental health. We are excited to collaborate with Incite Genomics to deliver this capability to our network.”

The nationwide availability of CNSDose reflects a shared commitment to advancing personalised healthcare and improving patient outcomes through innovative diagnostic solutions. With increasing recognition of the role genetics plays in drug response, CNSDose is well positioned to support clinicians in delivering safer and more effective treatments.

About Incite Genomics Incite Genomics is an Australian-based genomics company focused on developing and delivering clinically actionable genetic tests that support precision medicine. Its solutions are designed to integrate seamlessly into clinical workflows and provide meaningful insights to improve patient care.

About Australian Clinical Labs Australian Clinical Labs is one of Australia’s largest private providers of pathology services, offering a comprehensive range of diagnostic testing to clinicians, hospitals and patients nationwide.